

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number  
**WO 2005/012524 A1**

(51) International Patent Classification<sup>7</sup>: **C12N 15/11**,  
A61K 38/00

(21) International Application Number:  
PCT/GB2004/003235

(22) International Filing Date: 23 July 2004 (23.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0317466.1 25 July 2003 (25.07.2003) GB

(71) Applicant (for all designated States except US): **THE UNIVERSITY OF SHEFFIELD** [GB/GB]; Western Bank, Sheffield S10 2TN (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **HELLEDAY, Thomas** [SE/SE]; Erik Dahlbergsgatan 38, S-115 32 Stockholm (SE).

(74) Agent: **HARRISON GODDARD FOOTE**; 31 St. Saviourgate, York YO1 8NQ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention relates to the use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases caused by a defect in a gene that mediates homologous recombination.



**WO 2005/012524 A1**

USE OF RNAI INHIBITING PARP ACTIVITY FOR THE MANUFACTURE OF A MEDICAMENT FOR THE  
TREATMENT OF CANCER

This invention relates to the use of an agent that inhibits the activity of an enzyme which mediates the repair of DNA strand breaks in the treatment of certain forms of cancer in particular breast cancer.

Homologous recombination (HR) has been shown to play an important role in repair of damage occurring at DNA replication forks in mammalian cells (2). Thus, cells deficient in HR show retarded growth and exhibit higher level of genetic instability. It is believed that genetic instability due to loss of HR repair in human cancers significantly contributes to the development of cancer in these cells (1).

Post transcriptional modification of nuclear proteins by poly(ADP-ribosyl)ation (PARP) in response to DNA strand breaks plays an important role in DNA repair, regulation of apoptosis, and maintenance of genomic stability.

Poly(ADP-ribose) Polymerase (PARP-1) is an abundant nuclear protein in mammalian cells that catalyses the formation of poly(ADP-ribose) (PAR) polymers using  $\text{NAD}^+$  as substrate. Upon DNA damage, PARP-1 binds rapidly to a DNA strand break (single strand or double strand) and catalyses the addition of negatively charged PAR chains to itself (automodification) and other proteins (see [3, 4] for reviews). The binding of PARP-1 to DNA strand breaks is believed to protect DNA lesions from further processing until PARP-1 is dissociated from the break by the accumulated negative charge resulting from PAR polymers (5,6).

Although PARP-1 has been implicated in several nuclear processes, such as modulation of chromatin structure, DNA replication, DNA repair and transcription, PARP-1 knockout mice develop normally (7). Cells isolated from these mice exhibit a hyper recombination phenotype and genetic instability in the form of increased levels of SCE, micronuclei and tetraploidy (8-10). Genetic instability may also occur in these PARP-1 knockout mice through telomere shortening, increased frequency of chromosome fusion and aneuploidy (11), although all of these results could not be repeated in another set of PARP-1 knock-out mice (12). In the former mice knockout, PARP-1 null mutation rescue impaired V(D)J recombination in SCID mice (13).

These results support the view suggested by Lindahl and coworkers that PARP-1 has a protective role against recombination (5). They proposed that binding of PARP-1 to DNA strand breaks prevents the recombination machinery from recognizing and processing DNA lesions or, alternatively, that the negative charges accumulated following poly ADP-ribosylation repel adjacent recombinogenic DNA sequences. Only the latter model is consistent with inhibition of PARP-1 itself and expression of a dominant negative mutant PARP-1, inducing SCE, gene amplification and homologous recombination (HR [14-18]).

Studies based on treating cells with PARP inhibitors or cells derived from PARP-1 or PARP-2 knockout mice indicate that the suppression of PARP-1 activity increases cell susceptibility to DNA damaging agents and inhibits strand break rejoining (3, 4, 8-11, 19, 20, 47).

Inhibitors of PARP-1 activity have been used in combination with traditional anti-cancer agents such as radio therapy and chemotherapy (21). The inhibitors were used in combination with methylating agents, topoisomerase poisons and ionising radiations and were found to enhance the effectiveness of these forms of treatment. Such treatments, however, are known to cause damage and death to non cancerous or "healthy" cells and are associated with unpleasant side effects.

There is therefore a need for a treatment for cancer that is both effective and selective in the killing of cancer cells and which does not need to be administered in combination with radio or chemotherapy treatments.

The present inventors have surprisingly found that cells deficient in homologous recombination (HR) are hypersensitive to PARP inhibitors as compared to wild type cells. This is surprising since PARP-1 knockout mice live normally thereby indicating that PARP-1 is not essential for life. Thus, it could not be expected that cells would be sensitive to PARP inhibition.

According to a first aspect of the invention there is provided the use of an agent that inhibits the activity of an enzyme that mediates the repair of DNA strand breaks in the

manufacture of a medicament for the treatment of diseases that are caused by a genetic defect in a gene that mediates homologous recombination.

5 In a further aspect the invention provides a method of treatment of a disease or condition in a mammal, including human, which is caused by a genetic defect in a gene which mediates homologous recombination, which method comprises administering to the mammal a therapeutically effective amount of an agent which inhibits the activity of an enzyme which mediates repair of DNA strand breaks or other lesions present at replication forks.

10

In a preferred aspect said enzyme is PARP. In a further preferred aspect said agent is a PARP inhibitor or an RNAi molecule specific to PARP gene.

In a further preferred aspect, the use is in the treatment of cancer.

15

Preferably the medicament is a pharmaceutical composition consisting of the PARP inhibitor in combination with a pharmaceutically acceptable carrier or diluent.

20 The specific sensitivity of HR defective tumours to PARP-1 inhibition means that normally dividing cells in the patient will be unaffected by the treatment. Treatment of HR defective cancer cells using a PARP inhibitor also has the advantage that it does not need to be administered as a combination therapy along with conventional radio or chemotherapy treatments thereby avoiding the side effects associated with these conventional forms of treatment.

25

A genetic defect in a gene which mediates homologous recombination may be due to a mutation in, the absence of, or defective expression of, a gene encoding a protein involved in HR.

30 In a further aspect, the invention further provides the use of a PARP inhibitor in the manufacture of a medicament for inducing apoptosis in HR defective cells.

In another aspect the invention provides a method of inducing apoptosis in HR defective cells in a mammal which method comprises administering to the mammal a therapeutically effective amount of a PARP inhibitor.

- 5 By causing apoptosis in HR defective cells it should be possible to reduce or halt the growth of a tumour in the mammal.

Preferably, the HR defective cells are cancer cells.

- 10 Cancer cells defective in HR may partially or totally deficient in HR. Preferably the cancer cells are totally deficient in HR.

- The term "cancer" or "tumour" includes lung, colon, pancreatic, gastric, ovarian, cervical, breast or prostate cancer. The cancer may also include skin, renal, liver,  
15 bladder or cerebral cancer. In a preferred aspect, the cancer is in a mammal, preferably human.

- The cancer to be treated may be an inherited form of cancer wherein the patient to be treated has a familial predisposition to the cancer. Preferably, the cancer to be treated  
20 is gene-linked hereditary cancer. In a preferred embodiment of the invention the cancer is gene-linked hereditary breast cancer.

- In a preferred aspect, the PARP inhibitor is useful in the treatment of cancer cells defective in the expression of a gene involved in HR. Genes with suggested function in  
25 HR include XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1,  
30 Mus81, Emel, DDS1, BARD (see (2, 3, 5, 22-28) for reviews).

A gene involved in HR may be a tumour suppressor gene. The invention thus provides for the treatment of cancer cells defective in the expression of a tumour suppressor gene. Preferably, the tumour suppressor gene is BRCA1 or BRCA2.

Breast cancer is the most common cancer disease among women in the Western world today. Certain families have strong predisposition for breast cancer, which is often owing to an inherited mutation in one allele of either BRCA1 or BRCA2. However, these patients still maintain one functional allele. Thus, these patients develop normally and have no phenotypic consequence from this mutation. However, in one cell, the functional allele might be lost, making this cell cancerous and at the same time deficient in homologous recombination (HR). This step is critical for the onset of a tumour (1).

The present inventors have surprisingly found that BRCA2 deficient cells are 100 times more sensitive to the cytotoxicity of the PARP inhibitor, NU1025, than wild type cells.

Thus in a preferred aspect, the invention provides the use of a PARP inhibitor in the manufacture of a medicament for the treatment of cancer cells defective in HR, e.g due to the loss of BRCA1 and/or BRCA2 expression.

The cancer cells to be treated may be partially or totally deficient in BRCA1 or BRCA2 expression. BRCA1 and BRCA2 mutations can be identified using multiplex PCR techniques, array techniques (29, 30) or using other screens known to the skilled person.

PARP inhibitors useful in the present invention may be selected from inhibitors of PARP-1, PARP-2, PARP-3, PARP-4, tankyrase 1 or tankyrase 2 (see 31 for a review).

In a preferred embodiment, the PARP inhibitor useful in the present invention is an inhibitor of PARP-1 activity.

PARP inhibitors useful in the present invention include benzimidazole-carboxamides, quinazolin-4-[3H]-ones and isoquinoline derivatives (e.g. 2-(4-hydroxyphenyl)benzimidazole-4-carboxamide (NU1085), 8-hydroxy-2-methylquinazolin-4-[3H]one (NU1025); 6(5H)phenanthridinone; 3 aminobenzamide; benzimidazole-4-carboxamides (BZ1-6) and tricyclic lactam indoles (TI1-5) [32]. Further inhibitors of PARP may be identified either by design [33] or the novel FlashPlate assay [34].

The PARP inhibitor formulated as a pharmaceutical composition may be administered in any effective, convenient manner effective for targeting cancer cells including, for instance, administration by oral, intravenous, intramuscular, intradermal, intranasal, 5 topical routes among others. Carriers or diluents useful in the pharmaceutical composition may include, but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof.

10 In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion. The inhibitor may be administered directly to a tumour or may be targeted to the tumour via systemic administration.

15 A therapeutically effective amount of the inhibitor is typically one which is sufficient to achieve the desired effect and may vary according to the nature and severity of the disease condition, and the potency of the inhibitor. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease.

20 For administration to mammals, and particularly humans, it is expected that the daily dosage level of the active agent will be up to 100mg/kg, for example from 0.01mg/kg to 50 mg/kg body weight, typically up to 0.1, 0.5, 1.0, 2.0 5.0, 10, 15, 20 or 30mg/kg body weight. Ultimately, however, the amount of inhibitor administered and the frequency of administration will be at the discretion of a physician.

25 A therapeutic advantage of using PARP inhibitors to treat cancer cells is that only very low doses are needed to have a therapeutic effect in treating cancer thereby reducing systemic build up of the inhibitors and any associated toxic effects.

30 A preferred aspect of the invention provides an agent which is an inhibitory RNA (RNAi) molecule.

A technique to specifically ablate gene function is through the introduction of double stranded RNA, also referred to as inhibitory RNA (RNAi), into a cell which results in

the destruction of mRNA complementary to the sequence included in the RNAi molecule. The RNAi molecule comprises two complementary strands of RNA (a sense strand and an antisense strand) annealed to each other to form a double stranded RNA molecule. The RNAi molecule is typically derived from exonic or coding  
5 sequence of the gene which is to be ablated.

Preferably said RNAi molecule is derived from the nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

- 10 a) a nucleic acid sequence as represented by the sequence in Figure 9, 10, 11, 12, 13 or 14 or fragment thereof;
- b) a nucleic acid sequence which hybridises to the nucleic acid sequences of Figure 9, 10, 11, 12, 13 or 14 and encodes a gene for PARP;
- c) a nucleic acid sequence which comprise sequences which are degenerate as a result of the genetic code to the nucleic acid sequences defined in (a)  
15 and (b).

Recent studies suggest that RNAi molecules ranging from 100-1000bp derived from coding sequence are effective inhibitors of gene expression. Surprisingly, only a few molecules of RNAi are required to block gene expression which implies the  
20 mechanism is catalytic. The site of action appears to be nuclear as little if any RNAi is detectable in the cytoplasm of cells indicating that RNAi exerts its effect during mRNA synthesis or processing.

More preferably said RNAi molecule according has a length of between 10 nucleotide  
25 bases (nb) –1000nb. Even more preferably said RNAi molecule has a length of 10nb; 20nb; 30nb; 40nb; 50nb; 60nb; 70nb; 80nb; 90nb; or 100bp. Even more preferably still said RNAi molecule is 21nb in length.

Even more preferably still the RNAi molecule comprises the nucleic acid sequence  
30 aaa agc cau ggu gga gua uga (PARP-1)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence  
aag acc aau cuc ucc agu uca ac (PARP-2)

Even more preferably still the RNAi molecule consists of the nucleic acid sequence  
aag acc aac auc gag aac aac (PARP-3)

The RNAi molecule may comprise modified nucleotide bases.

5

Preferred features of each aspect of the invention are as for each of the other aspects  
*mutatis mutandis*.

The present invention will now be described by way of example only with reference  
10 to the accompanying figures, wherein:

Figure 1 is a graph demonstrating that HR deficient cells are hypersensitive to the  
toxic effect caused by inhibition of PARP-1. Colony outgrowth of the Chinese  
hamster cell lines AA8 (wild-type), irs1SF (deficient in HR[4]), CXR3 (irs1SF  
15 complemented with XRCC3 [2]), V79 (wild-type), irs1 (deficient in HR[5]) or  
irs1X2.2 (irs1 complimented with XRCC2 [1]) upon exposure to 3-AB (A), ISQ (B)  
or NU1025 (C). The means (symbols) and standard deviation (bars) of at least three  
experiments are shown. Colony outgrowth assay was used;

20 Figure 2 is a graph showing cell survival in the presence of PARP inhibitor NU1025  
in wt V79 cells, BRCA2 deficient VC-8 cells and VC-8 cells complimented with  
functional BRCA2 gene (VC-8#13, VC-8+B2). Colony outgrowth assay was used;

Figure 3 is a histogram showing the percentage of the cells in apoptosis following a  
25 72 hour incubation with NU1025;

Figure 4. (a) Western blot analysis of protein lysates isolated from MCF-7 (p53<sup>wt</sup>) or  
MDA-MB-231 (p53<sup>mut</sup>) breast cancer cells following 48 hours transfection with  
siRNA. (b) Colony outgrowth of siRNA-treated MCF-7 cells or (c) MDA-MB-231  
30 cells following exposure to the PARP inhibitor NU1025. The means (symbols) and  
standard deviation (bars) of at least three experiments are shown.

Figure 5. BRCA2 deficient cells fail to repair a recombination lesion formed at  
replication forks by inhibitors of PARP. (a) Visualization of double strand breaks

(DSBs) in BRCA2 proficient or deficient cells following a 24-hour treatment with NU1025 (0.1 mM) by pulse-field gel electrophoresis. Hydroxyurea 2 mM was used as a positive control. (b) Visualisation of  $\gamma$ H2Ax foci in untreated V-C8+B2 and V-C8 cells. Number of cells containing  $\gamma$ H2Ax foci (c) or RAD51 foci (d) visualised in V-C8+B2 and V-C8 cells following a 24-hour treatment with NU1025 (10  $\mu$ M). The means (symbols) and standard errors (bars) of three to nine experiments are shown. (e) A suggested model for cell death induced in BRCA2 deficient cells.

Figure 6. PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion, causing death in absence of BRCA2. (a) RT-PCR on RNA isolated from SW480SN.3 cells treated with BRCA2, PARP-1 and PARP-2 siRNA in combinations as shown for 48 hours. (b) Clonogenic survival following 48-hours depletion of BRCA2, PARP-1 and PARP-2. The means (symbols) and standard deviation (bars) of at least three experiments are shown. Two and three stars designate statistical significance in *t-test*  $p < 0.01$  and  $p < 0.001$ , respectively. (c) Western blot for PARP-1 in SW480SN.3 cells treated with different siRNA.

Figure 7. (a) Visualisation of PAR polymers in untreated and (b) thymidine treated V79 cells (5 mM for 24 hours). (c) Percentage cells containing >10 sites of PARP activity following treatment with hydroxyurea (0.2 mM) and thymidine (5 mM). At least 300 nuclei were counted for each treatment and experiment. (d) Survival of V-C8+B2 cells following co-treatment with hydroxyurea or (e) thymidine and NU1025 (10  $\mu$ M). (f) The activity of PARP was measured by the level of free NAD(P)H<sup>11</sup>, following treatment with MMS, hydroxyurea (0.5 mM) or thymidine (10 mM). The means (symbol) and standard deviation (error bars) from at least three experiments are depicted.

Figure 8. (a) Visualisation of PAR polymers in untreated V-C8 and (b) V-C8+B2 cells. (c) Quantification of percentage cells containing >10 sites of PARP activity in untreated V-C8 and V-C8+B2 cells. (d) Level of NAD(P)H measured in untreated V-C8 and V-C8+B2 cells. Three stars designate  $p < 0.001$  in *t-test*. (e) Visualization of RAD51 and sites of PARP activity in V79 cells following a 24-hour thymidine

treatment (5 mM). (f) A model for the role of PARP and HR at stalled replication forks.

Figure 9 is the human cDNA sequence of PARP-1;

Figure 10 is the human cDNA sequence of PARP-2;

Figure 11 is the human cDNA sequence of PARP-3;

Figure 12 is the human gDNA sequence of Tankyrase 1;

Figure 13 is the human mRNA sequence of Tankyrase 2;

Figure 14 is the human mRNA sequence of VPARP.

## **Materials and Methods**

### **Cytotoxicity of PARP inhibitors to HR-defective cells: XRCC2, XRCC3 or BRCA2**

#### ***Cell culture***

The irs1, irs1X2.1 and V79-4 cell lines were a donation from John Thacker [40] and the AA8, irs1SF and CXR3 cell lines were provided by Larry Thompson [41].

The VC-8, VC-8+B2, VC-8#13 were a gift from Malgorzata Zdzienicka [42]. All cell lines in this study were grown in Dulbecco's modified Eagle's Medium (DMEM) with 10% Foetal bovine serum and penicillin (100 U/ml) and streptomycin sulphate (100 µg/mL) at 37°C under an atmosphere containing 5% CO<sub>2</sub>.

#### ***Toxicity assay - colony outgrowth assay***

500 cells suspended in medium were plated onto a Petri dish 4 hours prior to the addition of 3-AB, ISQ or NU1025. ISQ and NU1025 were dissolved in DMSO to a final concentration of 0.2% in treatment medium. 7 - 12 days later, when colonies could be observed, these colonies were fixed and stained with methylene blue in

methanol (4 g/l). Colonies consisting of more than 50 cells were subsequently counted.

#### Apoptosis experiments

- 5 0.25x10<sup>6</sup> cells were plated onto Petri dishes and grown for 4 hours before treatment with NU1025. After 72 hours, cells were trypsinized and resuspended with medium containing any floating cells from that sample. The cells were pelleted by centrifugation and resuspended for apoptosis analysis with FITC-conjugated annexin-V and propidium iodine (PI) (ApoTarget, Biosource International) according to  
10 manufacturer's protocol. Samples were analysed by flow cytometry (Becton-Dickenson FACSsort, 488 nm laser), and percentage of apoptotic cells was determined by the fraction of live cells (PI-negative) bound with FITC-conjugated annexin-V.

#### 15 Immunofluorescence

- Cells were plated onto coverslips 4 h prior to 24-h treatments as indicated. Following treatments the medium was removed and coverslips rinsed once in PBS at 37°C and fixed as described elsewhere [2]. The primary antibodies and dilutions used in this study were; rabbit polyclonal anti PAR (Trevigen; 1:500), goat polyclonal anti Rad51  
20 (C-20, Santa Cruz; 1:200) and rabbit polyclonal anti Rad51 (H-92, Santa Cruz; 1:1000). The secondary antibodies were Cy-3-conjugated goat anti-rabbit IgG antibody (Zymed; 1:500), Alexa 555 goat anti-rabbit F(ab')<sub>2</sub> IgG antibody (Molecular Probes; 1:500), Alexa 546 donkey anti-goat IgG antibody (Molecular Probes; 1:500) and Alexa 488 donkey anti-rabbit IgG antibody (Molecular Probes; 1:500).  
25 Antibodies were diluted in PBS containing 3% bovine serum albumin. DNA was stained with 1 µg/ml To Pro (Molecular Probes). Images were obtained with a Zeiss LSM 510 inverted confocal microscope using planapochromat 63X/NA 1.4 oil immersion objective and excitation wavelengths 488, 546 and 630 nm. Through focus maximum projection images were acquired from optical sections 0.50 µm apart  
30 and with a section thickness of 1.0 µm. Images were processed using Adobe PhotoShop (Abacus Inc). At least 300 nuclei were counted on each slide and those containing more than 10 RAD51 foci or sites of PARP activity were classified as positive.

### PARP activity assays

A water-soluble tetrazolium salt (5mM WST-8) was used to monitor the amount of NAD(P)H through its reduction to a yellow coloured formazan dye[43]. 5000 cells were plated in at least triplicate into wells of a 96 well plate and cultured in 100µl normal growth media for 4 h at 37°C. CK8 buffer (Dojindo Molecular Technology, Gaithersburg, USA), containing WST-8, was then added either with or without treatment with DNA damaging agents at concentrations indicated. Reduction of WST-8 in the presence of NAD(P)H was determined by measuring visible absorbance (OD<sub>450</sub>) every 30 min. A medium blank was also prepared containing just media and CK8 buffer. Changes in NAD(P)H levels were calculated by comparing the absorbance of wells containing cells treated with DNA damaging agents and those treated with DMSO alone. Alternately relative levels of NAD(P)H in different cells lines were calculated after 4 h incubation in CK8 buffer.

The ability of NU1025 to inhibit PARP-1 activity was also assayed in permeabilised cells using a modification of the method of Halldorsson *et al* [44], and described in detail elsewhere [45]. Briefly: 300 µl of NU1025-treated (15 min) permeabilised cells were incubated at 26°C with oligonucleotide (final conc. 2.5 µg/ml), 75 µM NAD + [<sup>32</sup>P] NAD (Amersham Pharmacia, Amersham, UK) in a total volume of 400 µl. The reaction was terminated after 5 min by adding ice cold 10%TCA 10%Na Ppi for 60 min prior to filtering through a Whatman GF/C filter (LabSales, Maidstone, UK), rinsed 6x with 1% TCA 1% NaPpi, left to dry and incorporated radioactivity was measured to determine PARP-1 activity. Data are expressed as pmol NAD incorporated/10<sup>6</sup> cells by reference to [<sup>32</sup>P] NAD standards.

### Pulse-field gel electrophoresis

1.5x10<sup>6</sup> cells were plated onto 100 mm dishes and allowed 4 h for attachment. Exposure to drug was for 18 h after which cells were trypsinised and 10<sup>6</sup> cells melted into each 1% agarose insert. These inserts were incubated as described elsewhere (8) and separated by pulse-field gel electrophoresis for 24 h (BioRad; 120° angle, 60 to 240 s switch time, 4 V/cm). The gel was subsequently stained with ethidium bromide for analysis.

Predesigned BRCA2 SMARTpool and scrambled siRNAs were purchased (Dharmacon, Lafayette, CO). 10000 cells seeded onto 6 well plates and left over night before transfected with 100nM siRNA using Oligofectamine Reagent (Invitrogen) according to manufacturers instructions. Cells were then cultured in normal growth media for 48 h prior to trypsinisation and replating for toxicity assays. Suppression of BRCA2 was confirmed by Western blotting (as described previously [46]) of protein extracts treated with siRNA with an antibody against BRCA2 (Oncogene, Nottingham, UK).

## **EXAMPLES**

### **Homologous recombination deficient cells are hypersensitive to PARP-1 inhibition**

To investigate the involvement of HR in cellular responses to inhibition of PARP-1, the effects of PARP-1 inhibitors on the survival of HR repair deficient cell lines were studied. It was found that cells deficient in HR (i.e., *irs1SF* which is defective in *XRCC3* or *irs1* which is defective in *XRCC2* [see Table 1] were very sensitive to the toxic effect of 3-aminobenzamide (3-AB) and to two more potent inhibitors of PARP-1: 1,5-dihydroxyisoquinoline (ISQ; [37]) or 8-hydroxy-2-methylquinazolinone (NU1025 [38, 39]) (Figure 1). The sensitivity in *irs1SF* cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional *XRCC3* gene (*CXR3*). Similarly, the sensitivity in *irs1* cells to 3-AB, ISQ or NU1025 was corrected by the introduction of a cosmid containing a functional *XRCC2* gene (*irs1X2.2*).

### **BRCA2 deficient cells are hypersensitive to PARP-1 inhibition**

The survival of BRCA2 deficient cells (VC8) and wild type cells (V79Z) in the presence of inhibitors of PARP-1 was investigated. It was found that VC8 cells are very sensitive to the toxic effect of NU1025 (Figure 2). The sensitivity in VC8 cells was corrected by the introduction of a functional BRCA2 gene either on chromosome 13 (VC8#13) or on an overexpression vector (VC8+B2). This result demonstrates that the sensitivity to PARP-1 inhibitors is a direct consequence of loss of the BRCA2 function.

To investigate if inhibition of PARP-1 triggers apoptosis in BRCA2 deficient cells, the level of apoptosis 72 hours following exposure to NU1025 was investigated. It was found that NU1025 triggered apoptosis only in VC8 cells, showing that loss of PARP-1 activity in BRCA2 deficient cells triggers this means of death (Figure 3).

5

BRCA2 deficient breast cancer cells are hypersensitive to PARP-1 inhibition

It was examined whether the MCF7 (wild-type p53) and MDA-MB-231 (mutated p53) breast cancer cell lines displayed a similar sensitivity to NU1025 upon depletion of BRCA2. It was found that PARP inhibitors profoundly reduced the survival of MCF7 and MDA-MB-231 cells only when BRCA2 was depleted with a mixture of BRCA2 siRNA (Figure 4). This shows that BRCA2 depleted breast cancer cells are sensitive to PARP inhibitors regardless of p53 status.

10

BRCA2 deficient cells die from PARP-1 inhibition in absence of DNA double-strand breaks (DSBs) but in presence of  $\gamma$ H2Ax

15

HR is known to be involved in the repair of DSBs and other lesions that occur during DNA replication [2]. To determine whether the sensitivity of BRCA2 deficient cells is the result of an inability to repair DSBs following NU1025 treatment, the accumulation of DSBs in V79 and V-C8 cells was measured following treatments with highly toxic levels of NU1025. It was found that no DSBs were detectable by pulsed field gel electrophoretic analysis of DNA obtained from the treated cells (Figure 5A), suggesting that low levels of DSBs or other recombinogenic substrates accumulated following PARP inhibition in HR deficient cells, which trigger  $\gamma$ H2Ax (Figure 5B). The reason why BRCA2 deficient cells die following induction of these recombinogenic lesions is likely to be due to an inability to repair such lesions. To test this, the ability of BRCA2 deficient V-C8 cells and BRCA2 complimented cells to form RAD51 foci in response to NU1025 was determined. It was found that RAD51 foci were indeed induced in V-C8+B2 cells following treatment with NU1025 (statistically significant in *t-test*  $p < 0.05$ ; Figure 5D). This indicates that the recombinogenic lesions trigger HR repair in these cells allowing them to survive. In contrast, the BRCA2 deficient V-C8 cells were unable to form RAD51 foci in response to NU1025 treatment (Figure 5D) indicating no HR, which would leave the recombinogenic lesions unrepaired and thus cause cell death.

20

25

30

PARP-1 and not PARP-2 is important in preventing formation of a recombinogenic lesion

There are two major PARPs present in the nucleus in mammalian cells, PARP-1 and PARP-2 and all reported PARP inhibitors inhibit both. In order to distinguish which PARP was responsible for the effect, we tested if the absence of PARP-1 and/or PARP-2 results in accumulation of toxic lesions, by depleting these and BRCA2 with siRNA in human cells (Figure 6a). We found that the clonogenic survival was significantly reduced when both PARP-1 and BRCA2 proteins were co-depleted from human cells (Figure 6b). Depletion of PARP-2 with BRCA2 had no effect on the clonogenic survival and depletion of PARP-2 in PARP-1 and BRCA2 depleted cells did not result in additional toxicity. These results suggest that PARP-1 and not PARP-2 is responsible for reducing toxic recombinogenic lesions in human cells. The cloning efficiency was only reduced to 60% of control in PARP-1 and BRCA2 co-depleted cells, while no HR deficient cells survived treatments with PARP inhibitors. This is likely to do with incomplete depletion of the abundant PARP-1 protein by siRNA (Figure 6c), which might be sufficient to maintain PARP-1 function in some of the cells.

PARP-1 is activated by replication inhibitors

HR is also involved in repair of lesions occurring at stalled replication forks, which may not involve detectable DSBs [2]. To test if PARP has a role at replication forks, PARP activation in cells treated cells with agents (thymidine or hydroxyurea) that retard or arrest the progression of DNA replication forks was examined. Thymidine depletes cells of dCTP and slows replication forks without causing DSBs. Hydroxyurea depletes several dNTP and block the replication fork, which is associated with the formation of DSBs at replication forks [2]. Both of these agents potently induce HR [2]. V79 hamster cells treated for 24 hours with thymidine or hydroxyurea were stained for PAR polymers. This revealed a substantial increase in the number of cells containing sites of PARP activity (Figure 7C). This result suggests a function for PARP at stalled replication forks. It was also shown that inhibition of PARP with NU1025 enhances the sensitivity to thymidine or hydroxyurea in V-C8+B2 cells (Figure 7D,E). This result suggests that PARP activity is important in

repair of stalled replication forks or alternatively that it prevents the induction of death in cells with stalled replication forks.

PARP is rapidly activated at DNA single-strand breaks (SSB) and attracts DNA repair enzymes [3-6]. Methylmethane sulphonate (MMS) causes alkylation of DNA, which is repaired by base excision repair. PARP is rapidly activated by the SSB-intermediate formed during this repair, which depletes the NAD(P)H levels (Figure 7F). We found that the activation of PARP and reduction of NAD(P)H levels is much slower following thymidine or hydroxyurea treatments. This slow PARP activation can be explained by the indirect action of thymidine and hydroxyurea and the time required to accumulate stalled replication forks as cells enter the S phase of the cell cycle.

#### PARP-1 and HR have separate roles at stalled replication forks

The number sites of PARP activity in untreated BRCA2 deficient V-C8 cells was determined. It was found that more V-C8 cells contain sites of PARP activity compared to V-C8+B2 cells (Figure 8A,B,C). Also, the V-C8 cells have lower free NAD(P)H levels than the corrected cells (Figure 8D), as a likely result of the increased PARP activity. Importantly these sites of PARP activity do not overlap with RAD51 foci (Figure 8E).

The results herein suggest that PARP and HR have separate roles in the protection or rescue of stalled replication forks (Figure 8F). A loss of PARP activity can be compensated by increased HR while a loss of HR can be compensated by increased PARP activity. However, loss of both these pathways leads to accumulation of stalled replication forks and to death, as in the case of PARP inhibited BRCA2 deficient cells.

As shown in the model outlined in Figure 8F PARP and HR have complementary roles at stalled replication forks. (i) Replication forks may stall when encountering a roadblock on the DNA template. In addition, they may also stall temporarily, due to lack of dNTPs or other replication co-factors. (ii) PARP binds stalled replication forks or other replication-associated damage, triggering PAR polymerization. Resulting negatively charged PAR polymers may protect stalled replication forks, by repelling

proteins that normally would process replication forks (e.g., resolvases), until the replication fork can be restored spontaneously when dNTPs or other co-factors become available. Alternatively, PAR polymers or PARP may attract proteins to resolve the replication block by other means. (iii) In absence of PARP activity, HR may be used as an alternative pathway to repair stalled replication forks. This compensatory model explains the increased level of HR and RAD51 foci found in PARP deficient cells<sup>3-5</sup> and higher PARP activity found in HR deficient cells (i.e. V-C8). Spontaneous replication blocks/lesions are only lethal in the absence of both PARP and HR.

**Table 1.** Genotype and origin of cell lines used in this study.

Cell line	Genotype	Defect	Origin	Reference
AA8	Wt	Wt	CHO	[41]
irs1SF	<i>XRCC3</i> <sup>-</sup>	<i>XRCC3</i> <sup>-</sup> , deficient in HR	AA8	[41]
CXR3	<i>XRCC3</i> <sup>-</sup> + <i>hXRCC3</i>	Wt	irs1SF	[41]
V79-4	Wt	Wt	V79	[40]
irs1	<i>XRCC2</i> <sup>-</sup>	<i>XRCC2</i> <sup>-</sup> , deficient in HR	V79-4	[40]
irs1X2.2	<i>XRCC2</i> <sup>-</sup> + <i>hXRCC2</i>	Wt	irs1	[40]
V79-Z	Wt	Wt	V79	[42]
VC8	<i>BRCA2</i> <sup>-</sup>	<i>BRCA2</i> <sup>-</sup> , deficient in HR	V79-Z	[42]
VC8#13	<i>BRCA2</i> <sup>-</sup> + <i>hBRCA2</i>	Wt	VC8	[42]
VC8+B2	<i>BRCA2</i> <sup>-</sup> + <i>hBRCA2</i>	Wt	VC8	[42]

## REFERENCES:

- [1] A.R. Venkitaraman Cancer susceptibility and the functions of BRCA1 and BRCA2, *Cell* 108 (2002) 171-182.
- 5 [2] C. Lundin, K. Erixon, C. Arnaudeau, N. Schultz, D. Jenssen, M. Meuth and T. Helleday Different roles for nonhomologous end joining and homologous recombination following replication arrest in mammalian cells, *Mol Cell Biol* 22 (2002) 5869-5878.
- 10 [3] D. D'Amours, S. Desnoyers, I. D'Silva and G.G. Poirier Poly(ADP-ribose)ation reactions in the regulation of nuclear functions, *Biochem J* 342 (1999) 249-268.
- [4] Z. Herceg and Z.Q. Wang Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death, *Mutat Res* 477 (2001) 97-110.
- 15 [5] T. Lindahl, M.S. Satoh, G.G. Poirier and A. Klungland Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks, *Trends Biochem Sci* 20 (1995) 405-411.
- [6] M.S. Satoh and T. Lindahl Role of poly(ADP-ribose) formation in DNA repair, *Nature* 356 (1992) 356-358.
- 20 [7] S. Shall and G. de Murcia Poly(ADP-ribose) polymerase-1: what have we learned from the deficient mouse model?, *Mutat Res* 460 (2000) 1-15.
- [8] Z.Q. Wang, L. Stingl, C. Morrison, M. Jantsch, M. Los, K. Schulze-Osthoff and E.F. Wagner PARP is important for genomic stability but dispensable in apoptosis, *Genes Dev* 11 (1997) 2347-2358.
- 25 [9] C.M. Simbulan-Rosenthal, B.R. Haddad, D.S. Rosenthal, Z. Weaver, A. Coleman, R. Luo, H.M. Young, Z.Q. Wang, T. Ried and M.E. Smulson Chromosomal aberrations in PARP(-/-) mice: genome stabilization in immortalized cells by reintroduction of poly(ADP-ribose) polymerase cDNA, *Proc Natl Acad Sci U S A* 96 (1999) 13191-13196.
- 30 [10] J.M. de Murcia, C. Niedergang, C. Trucco, M. Ricoul, B. Dutrillaux, M. Mark, F.J. Oliver, M. Masson, A. Dierich, M. LeMeur, C. Walztinger, P. Chambon and G. de Murcia Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells, *Proc Natl Acad Sci U S A* 94 (1997) 7303-7307.

- [11] F. d'Adda di Fagagna, M.P. Hande, W.M. Tong, P.M. Lansdorp, Z.Q. Wang and S.P. Jackson Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability, *Nat Genet* 23 (1999) 76-80.
- [12] E. Samper, F.A. Goytisolo, J. Menissier-de Murcia, E. Gonzalez-Suarez, J.C. Cigudosa, G. de Murcia and M.A. Blasco Normal telomere length and chromosomal end capping in poly(ADP-ribose) polymerase-deficient mice and primary cells despite increased chromosomal instability, *J Cell Biol* 154 (2001) 49-60.
- [13] C. Morrison, G.C. Smith, L. Stengl, S.P. Jackson, E.F. Wagner and Z.Q. Wang Genetic interaction between PARP and DNA-PK in V(D)J recombination and tumorigenesis, *Nat Genet* 17 (1997) 479-482.
- [14] V. Schreiber, D. Hunting, C. Trucco, B. Gowans, D. Grunwald, G. De Murcia and J.M. De Murcia A dominant-negative mutant of human poly(ADP-ribose) polymerase affects cell recovery, apoptosis, and sister chromatid exchange following DNA damage, *Proc Natl Acad Sci U S A* 92 (1995) 4753-4757.
- [15] J.H. Kupper, M. Muller and A. Burkle Trans-dominant inhibition of poly(ADP-ribosyl)ation potentiates carcinogen induced gene amplification in SV40-transformed Chinese hamster cells, *Cancer Res* 56 (1996) 2715-2717.
- [16] J. Magnusson and C. Ramel Inhibitor of poly(ADP-ribose)transferase potentiates the recombinogenic but not the mutagenic action of alkylating agents in somatic cells in vivo in *Drosophila melanogaster*, *Mutagenesis* 5 (1990) 511-514.
- [17] A.S. Waldman and B.C. Waldman Stimulation of intrachromosomal homologous recombination in mammalian cells by an inhibitor of poly(ADP-ribosylation), *Nucleic Acids Res* 19 (1991) 5943-5947.
- [18] A. Semionov, D. Cournoyer and T.Y. Chow Inhibition of poly(ADP-ribose)polymerase stimulates extrachromosomal homologous recombination in mouse Ltk-fibroblasts, *Nucleic Acids Res* 27 (1999) 4526-4531.
- [19] F. Dantzer, V. Schreiber, C. Niedergang, C. Trucco, E. Flatter, G. De La Rubia, J. Oliver, V. Rolli, J. Menissier-de Murcia and G. de Murcia Involvement of poly(ADP-ribose) polymerase in base excision repair, *Biochimie* 81 (1999) 69-75.

- [20] F. Dantzer, G. de La Rubia, J. Menissier-De Murcia, Z. Hostomsky, G. de Murcia and V. Schreiber Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1, *Biochemistry* 39 (2000) 7559-7569.
- [21] L. Tentori, I. Portarena and G. Graziani Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors, *Pharmacol Res* 45 (2002) 73-85.
- [22] T. Lindahl and R.D. Wood Quality control by DNA repair, *Science* 286 (1999) 1897-1905.
- [23] K.W. Caldecott DNA single-strand break repair and spinocerebellar ataxia, *Cell* 112 (2003) 7-10.
- [24] D. D'Amours and S.P. Jackson The Mre11 complex: at the crossroads of dna repair and checkpoint signalling, *Nat Rev Mol Cell Biol* 3 (2002) 317-327.
- [25] A.D. D'Andrea and M. Grompe The Fanconi anaemia/BRCA pathway, *Nat Rev Cancer* 3 (2003) 23-34.
- [26] S.P. Jackson Sensing and repairing DNA double-strand breaks, *Carcinogenesis* 23 (2002) 687-696.
- [27] R. Kanaar, J.H. Hoeijmakers and D.C. van Gent Molecular mechanisms of DNA double strand break repair, *Trends Cell Biol* 8 (1998) 483-489.
- [28] D.C. van Gent, J.H. Hoeijmakers and R. Kanaar Chromosomal stability and the DNA double-stranded break connection, *Nat Rev Genet* 2 (2001) 196-206.
- [29] S.L. Neuhausen and E.A. Ostrander Mutation testing of early-onset breast cancer genes BRCA1 and BRCA2, *Genet Test* 1 (1997) 75-83.
- [30] G. Kuperstein, W.D. Foulkes, P. Ghadirian, J. Hakimi and S.A. Narod A rapid fluorescent multiplexed-PCR analysis (FMPA) for founder mutations in the BRCA1 and BRCA2 genes, *Clin Genet* 57 (2000) 213-220.
- [31] A. Chiarugi Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited, *Trends Pharmacol Sci* 23 (2002) 122-129.
- [32] C.R. Calabrese, M.A. Batey, H.D. Thomas, B.W. Durkacz, L.Z. Wang, S. Kyle, D. Skalitzky, J. Li, C. Zhang, T. Boritzki, K. Maegley, A.H. Calvert, Z. Hostomsky, D.R. Newell and N.J. Curtin Identification of Potent Nontoxic Poly(ADP-Ribose) Polymerase-1 Inhibitors: Chemopotentiation and Pharmacological Studies, *Clin Cancer Res* 9 (2003) 2711-2718.
- [33] D. Ferraris, Y.S. Ko, T. Pahutski, R.P. Ficco, L. Serdyuk, C. Alemu, C. Bradford, T. Chiou, R. Hoover, S. Huang, S. Lautar, S. Liang, Q. Lin, M.X.

- Lu, M. Mooney, L. Morgan, Y. Qian, S. Tran, L.R. Williams, Q.Y. Wu, J. Zhang, Y. Zou and V. Kalish Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries, *J Med Chem* 46 (2003) 3138-3151.
- [34] K.J. Dillon, G.C. Smith and N.M. Martin A FlashPlate assay for the identification of PARP-1 inhibitors, *J Biomol Screen* 8 (2003) 347-352.
- [35] A.J. Pierce, R.D. Johnson, L.H. Thompson and M. Jasin XRCC3 promotes homology-directed repair of DNA damage in mammalian cells, *Genes Dev* 13 (1999) 2633-2638.
- [36] R.D. Johnson, N. Liu and M. Jasin Mammalian XRCC2 promotes the repair of DNA double-strand breaks by homologous recombination, *Nature* 401 (1999) 397-399.
- [37] G.M. Shah, D. Poirier, S. Desnoyers, S. Saint-Martin, J.C. Hoflack, P. Rong, M. ApSimon, J.B. Kirkland and G.G. Poirier Complete inhibition of poly(ADP-ribose) polymerase activity prevents the recovery of C3H10T1/2 cells from oxidative stress, *Biochim Biophys Acta* 1312 (1996) 1-7.
- [38] R.J. Griffin, S. Srinivasan, K. Bowman, A.H. Calvert, N.J. Curtin, D.R. Newell, L.C. Pemberton and B.T. Golding Resistance-modifying agents. 5. Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP), *J Med Chem* 41 (1998) 5247-5256.
- [39] S. Boulton, L.C. Pemberton, J.K. Porteous, N.J. Curtin, R.J. Griffin, B.T. Golding and B.W. Durkacz Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors, *Br J Cancer* 72 (1995) 849-856.
- [40] C.S. Griffin, P.J. Simpson, C.R. Wilson and J. Thacker Mammalian recombination-repair genes XRCC2 and XRCC3 promote correct chromosome segregation, *Nat Cell Biol* 2 (2000) 757-761.
- [41] R.S. Tebbs, Y. Zhao, J.D. Tucker, J.B. Scheerer, M.J. Siciliano, M. Hwang, N. Liu, R.J. Legerski and L.H. Thompson Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene, *Proc Natl Acad Sci U S A* 92 (1995) 6354-6358.

- [42] M. Kraakman-van der Zwet, W.J. Overkamp, R.E. van Lange, J. Essers, A. van Duijn-Goedhart, I. Wiggers, S. Swaminathan, P.P. van Buul, A. Errami, R.T. Tan, N.G. Jaspers, S.K. Sharan, R. Kanaar and M.Z. Zdzienicka Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions, Mol Cell Biol 22 (2002) 669-679.
- [43] J. Nakamura, S. Asakura, S.D. Hester, G. de Murcia, K.W. Caldecott and J.A. Swenberg Quantitation of intracellular NAD(P)H can monitor an imbalance of DNA single strand break repair in base excision repair deficient cells in real time, Nucleic Acids Res 31 (2003) e104.
- [44] H. Halldorsson, D.A. Gray and S. Shall Poly (ADP-ribose) polymerase activity in nucleotide permeable cells, FEBS Lett 85 (1978) 349-352.
- [45] K. Grube, J.H. Kupper and A. Burkle Direct stimulation of poly(ADP ribose) polymerase in permeabilized cells by double-stranded DNA oligomers, Anal Biochem 193 (1991) 236-239.
- [46] C. Lundin, N. Schultz, C. Arnaudeau, A. Mohindra, L.T. Hansen and T. Helleday RAD51 is Involved in Repair of Damage Associated with DNA Replication in Mammalian Cells, J Mol Biol 328 (2003) 521-535.
- [47] Schreider et al., Journal of Biological Chemistry 277: 23028-23036 (2002).

CLAIMS

1. Use of an agent that inhibits the activity of an enzyme that mediates repair of a DNA strand break in the manufacture of a medicament for the treatment of diseases  
5 caused by a defect in a gene that mediates homologous recombination.

2. The use as claimed in claim 1 wherein the enzyme is poly(ADP-ribose) polymerase (PARP).

10 3. The use as claimed in claim 2 wherein the agent is a PARP inhibitor.

4. The use as claimed in claim 3 wherein the PARP inhibitor is selected from the group consisting of PARP-1, PARP-2, PARP-3, PARP-4, tankyrase 1 and tankyrase  
2.

15

5. The use as claimed in claim 4 wherein the PARP is PARP-1.

6 The use as claimed in claim 1 or claim 2 wherein the agent is an RNAi molecule specific to a PARP gene.

20

7. The use as claimed in claim 6 wherein the RNAi molecule is derived from a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of:

25 a) a nucleic acid sequence as represented by the sequence in Figure 9, 10, 11, 12, 13 or 14, or a fragment thereof;

b) a nucleic acid sequence which hybridises to the nucleic acid sequences of Figure 9, 10, 11, 12, 13 or 14, and encodes a gene for PARP; or

30 c) a nucleic acid sequence which comprises sequences which are degenerate as a result of the genetic code to the nucleic acid sequences defined in (a) and (b).

8. The use as claimed in claim 6 or 7 wherein the RNAi molecule comprises the nucleic acid sequence aaa agc cau ggu gga gua uga.

9. The use as claimed in claim 6 or 7 wherein the RNAi molecule consists of the nucleic acid sequence aag acc aau cuc ucc agu uca ac.
10. The use as claimed in claim 6 or 7 wherein the RNAi molecule consists of the nucleic acid sequence aag acc aac auc gag aac aac.
11. The use as claimed in any preceding claim wherein the defect is a mutation in a gene encoding a protein involved in HR.
12. The use as claimed in any of claims 1 to 10 wherein the defect is the absence of a gene encoding a protein involved in HR.
13. The use as claimed in any of claims 1 to 10 wherein the defect is in the expression of a gene encoding a protein involved in HR.
14. The use as claimed in any preceding claim wherein the gene that mediates HR is selected from the group consisting of XRCC1, ADPRT (PARP-1), ADPRTL2 (PARP-2), CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51B, RAD51C, RAD51D, DMC1, XRCC2, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NBS1, WRN, BLM, Ku70, Ku80, ATM, ATR, chk1, chk2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9, FEN-1, Mus81, Eme1, DDS1 and BARD.
15. The use as claimed in any preceding claim in the treatment of cancer.
16. The use as claimed in claim 15 wherein the cancer is selected from the group consisting of lung, colon, pancreatic, gastric, ovarian, cervical, breast and prostate cancer.
17. The use as claimed in claim 15 or 16 wherein the cancer is in a human.
18. The use as claimed in any of claims 15 to 17 wherein the cancer is gene-linked hereditary cancer.

19. The use as claimed in claim 18 wherein the cancer is breast cancer.

20. The use as claimed in any of claims 15 to 19 wherein the cancer cells to be treated are defective in BRCA1 expression.

5

21. The use as claimed in any of claims 15 to 19 wherein the cancer cells to be treated are defective in BRCA2 expression.

22. The use as claimed in claim 20 or 21 wherein the cancer cells are partially deficient in BRCA1 and/or BRCA2 expression.

10

23. The use as claimed in claim 20 or 21 wherein the cancer cells are totally deficient in BRCA1 and/or BRCA2 expression.

24. The use as claimed in any preceding claim wherein the gene that mediates HR is a tumour suppressor gene.

15

25. The use as claimed in claim 24 wherein the tumour suppressor gene is BRCA1.

26. The use as claimed in claim 24 wherein the tumour suppressor gene is BRCA2

20

27. Use of a PARP inhibitor in the manufacture of a medicament for inducing apoptosis in HR defective cells.

28. The use as claimed in claim 27 wherein the HR defective cells are cancer cells.

25

29. The use as claimed in claim 28 wherein the cancer cells defective in HR are partially deficient in HR.

30. The use as claimed in claim 28 wherein the cancer cells defective in HR are totally deficient in HR.

30

31. A method of treatment of a disease or condition in a mammal, including human, which is caused by a genetic defect in a gene that mediates homologous

recombination, which method comprises administering to the mammal a therapeutically effective amount of an agent that inhibits the activity of an enzyme that mediates repair of DNA strand breaks.

- 5 32. A method of inducing apoptosis in HR defective cells in a mammal which method comprises administering to the mammal a therapeutically effective amount of a PARP inhibitor.

5 Figure 1.




Figure 2.




Figure 3




Figure 4









Figure 5A



6/20







FIG. 6







FIG. 7




FIGURE 9

1 cgcccgccca gccccggggg cagggaaagc ctaaattacg gaattaccgc gagcaaggag  
61 cgcggaatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tgatgggaat  
121 ctttgcaaat tgtatcttct gtttgaaagt gaagtactta cctcagcagc agaagaaaaa  
181 gctacaaact gacattaagg aaaatggcgg aaagttttcc ttttcgttaa atcctcagt  
241 cacacatata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca  
301 aaagaaccac gttcatattg caaaccaga ttttatatgg aaatctatca gagaaaagag  
361 actcttggat gtaaagaatt atgacctta taagcccctg gacatcacac cacctcctga  
421 tcagaaggcg agcagttctg aagtgaanaac agaaggtcta tgcccggaca gtgccacaga  
481 ggaggaagac actgtggaac tcaactgagtt tggatgcag aatgttgaaa ttctctatct  
541 tctcaagat tttgaagttg caaaatataa caccttggag aaagtgggaa tggagggagg  
601 ccaggaagct gtggtggtgg agcttcagtg ttcgcgggac tccagggact gtccttctc  
661 gatatctca cacttctcc tggatgatgg catggagact agaagacagt ttgctataaa  
721 gaaaacctct gaagatgcaa gtgaatactt tgaanaattac attgaagaac tgaagaaaca  
781 aggtattcta ctaagagaac atttcacacc tgaagcaacc caattagcat ctgaacaatt  
841 gcaagcattg cttttggagg aagtcagaa ttcaagcact ctgagccaag aggtgagcga  
901 tttagtagag atgatttggg cagaggccct gggccacctg gaacacatgc ttctcaagcc  
961 agtgaacagg attagcctca acgatgtgag caaggcagag gggattctcc ttctagttaa  
1021 ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagtttta  
1081 cagactgata cctcaciaag gcacaatgcc caaagaagtg aacctgggac tattggctaa  
1141 gaaagcagac ctctgccagc taataagaga catggttaat gtctgtgaaa ctaatttgc  
1201 caaacccaac ccaccatccc tggccaaata ccgagctttg aggtgcaaaa ttgagcatgt  
1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gttttgcaga atcatcacag  
1321 taagagccca gtggatgtct tgcagatatt tagagtggc agagtgaatg aaaccacaga  
1381 gtttttgagc aaacttggtg atgtgaggcc ctgttgcat ggttctctg tacaaaacat  
1441 cgtgggaatc ttgtgtcag ggttgctttt acccaaagta gtggaagatc gtggtgtgca  
1501 aagaacagac gtcggaacc ttggaagtgg gatttattc agtgattcgc tcagtacaag  
1561 tatcaagtac tcaccccgg gagagacaga tggcaccaga ctctgtctca tttgtgacgt  
1621 agccctcgga aagtgtatgg acttacatga gaaggacttt tcttaactg aagcaccacc  
1681 aggtacgac agtgtcatg gagtttaca aacagcctct gtcaccacag actttgagga  
1741 tgatgaattt gttgtctata aaaccaatca gggtaaaatg aaatatatta ttaaattttc  
1801 catgcctgga gatcagataa aggactttca tctagtgtat catactgaat tagaggaata  
1861 cagacctgag ttttcaatt ttcaaaggt tgaagattac cagtaccag atgcaaaaac  
1921 ttccagcagc accaaggccg gcctccagga tgcttctggg aacttgggtc ctctggagga  
1981 tgtccacatc aaaggagaa tcatagacac ttagccag gtcattgttt ttcagacata  
2041 cacaataaaa agtcacgtgc ccattgaggc aaaatatatc tttccttgg atgacaaggc  
2101 cgctgtgtgt ggcttcgaag ccttcatcaa tgggaagcac atagttggag agattaaaga  
2161 gaaggaagaa gccagcaag agtacctaga agccgtgacc cagggccatg gcgcttacct  
2221 gatgagtcag gatgctccg acgtttttac tgaagtgtt ggaaacttac ccctaaggc  
2281 taaggttctt ataaaaatta cctacatcac agaactcagc atctgggca ctgttggtgt  
2341 ctttttcatt cccgccaccg tagcaccctg gcaacaggac aaggctttga atgaaaacct  
2401 tcaggataca gtagagaaga ttgtataaa agaaatagga acaaagcaaa gcttctctt  
2461 gactatgtct attgagatgc cgtacgtgat tgaattcatt ttacgtgata ctcataaact  
2521 gaaacaaaag cgcacagact gcaaagctgt cattagcacc atggaaggca gtccttaga  
2581 cagcagtgga ttttctctcc acatcggtt gtctgtgcc tatctccaa gaatgtgggt  
2641 tgaanaacat ccagaaaaag aaagcgaggc ttgcatgctt gtcttcaac ccgatctga  
2701 tgtcgacctc cctgacctag ccaatgagag cgaagtgatt attgtcttg actgctccag  
2761 ttccatggag ggtgtgacat tcttgcaagc caaggaaatc gccttgcag cgctgtcctt

2821 ggtgggtgag aagcagaaag taaatattat ccagttcggc acaggttaca aggagctatt  
2881 ttctatcct aagcatatca caagcaatac cgcggcagca gagttcatca tgtctgccac  
2941 acctaccatg gggaacacag acttctggaa aacactccga tctcttagct tattgtaccc  
3001 tgctcgaggg tcacggaaca tctctctggt gtctgatggg cactctcagg atgagagcct  
3061 gacattacag ctctggaaga ggagccgccc gcacaccagg ttattcgct gcggtatcgg  
3121 ttctacagca aatcgtcacg tcttaaggat ttgtcccag tgtggtgccg gagtattga  
3181 atattttaat gcaaaatcca agcatagtig gagaaaacag atagaagacc aatgaccag  
3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc  
3301 gcccagggcc ctgcaggccc cagcccagggt gccatccttg tticgcaatg atcgactcct  
3361 tgtctatgga ttacttctc actgcacaca ggcaactctg tgtgcactaa ttaagagaa  
3421 agaattttgt acaatggtgt cgactactga gcttcagaag acaactggaa ctatgatcca  
3481 caagctggca gcccagagctc taatcagaga ttatgaagat ggcatcttc acgaaaatga  
3541 aaccagtcct gagatgaaaa acaaacctt gaaatctctg attattaaac tcagtaaaga  
3601 aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaagg atgagaatga  
3661 gtcacctttt cctgatattc caaaagtctc tgaacttatt gccaaagaag atgtagactt  
3721 cctgccctac atgagctggc aggggggaacc ccaagaagcc gtcaggaacc agtctctttt  
3781 agcatcctct gagtggccag aattacgttt atccaaacga aaacatagga aaattccatt  
3841 ttccaaaaga aaaatggaat tatctcagcc agaagtttct gaagattttg aagaggatgc  
3901 cttaggtgta ctaccagctt tcacatcaaa ttggaacgt ggacgtgtgg aaaagctatt  
3961 ggatttaagt tggacagagt catgtaaacc aacagcaact gaaccactat ttaagaaagt  
4021 cagtccatgg gaaacatcta ctctagctt ttctctatt ttggctccgg ccgttggttc  
4081 ctatcttacc ccgactaccg gcgtcacag tctgtctcc ttgtctttg cctcatatcg  
4141 tcaggtagct agtttcggtt cagctgctcc tcccagacag ttgatgcat ctcaattcag  
4201 ccaaggccct gtgcctggca ctgtgtctga ctggatccca cagtcggcgt ctgtccac  
4261 aggacctccc cagaaccac ctctgcacc ctattgtggc attgttttt caggagctc  
4321 attagctct gcacagtctg ctccactgca acatcctgga ggctttacta ccaggccttc  
4381 tgctggcacc ttccctgagc tggattctcc ccagcttcat ttctctctc ctacagacc  
4441 tgatccatc agaggtttg ggtcttatca tccctctgct tactctcctt ttcatttca  
4501 acctccgca gcctctttga ctgccaacct taggctgcca atggcctctg ctttacctga  
4561 ggctctttgc agtcagtccc ggactacccc agtagatctc tgtctctag aagaatcagt  
4621 aggcagctc gaaggaagtc gatgtctgt cttgtcttt caaagttctg acacagaaag  
4681 tgatgagcta tcagaagtac ttcaagacag ctgctttta caaataaaat gtgatacaa  
4741 agatgacagt atcccgtgct ttctggaagt aaaagaagag gatgaaatag tgtgcacaca  
4801 aactggcag gatgctgtgc ctggacaga actcctcagt ctacagacag aggatggctt  
4861 ctggaaactt acaccagaac tgggacttat attaaatctt aatacaaatg gttgcacag  
4921 ctttcttaa caaaaaggca ttcaatctct aggtgtaaaa ggaagagaat gtctctgga  
4981 cctaattgcc acaatgctgg tactacagtt tattgcacc aggttggaag aagagggaat  
5041 agtgttcaa tcaatgatga aatggatga ccttctatt tccaggaata ttccctgggc  
5101 tttagaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc  
5161 tatctgccc cggcttgaac tggggaacga ctgggactct gccaccaagc agttgctggg  
5221 actccagccc ataagcactg tgtccctct tcatagagtc ctccattaca gtcaaggcta  
5281 agtcaaatga aactgaattt taaactttt gcatgcttct atgtagaaa taatcaaatg  
5341 ataatagata cttataatga aacttcatta aggtttcatt cagtgtagca attactgtct  
5401 ttaaaaata agtgaagaa gaattactt aatcaactaa caagcaataa taaaatgaaa  
5461 cttaaaat

Figure 10

1 ctagaattca gcgccgctg aattctaggg ggcgcggcgg cgacggagca ccggcggcgg  
61 cagggcgaga gcattaaatg aaagcaaaag agttaataat ggcaacacgg ctccagaaga  
121 ctcttccct gccaaagaaa ctgtagatg ccagagacag gagtcgaaa agatgcctgt  
181 ggctggagga aaagctaata aggacaggac agaagacaag caagatggta tgccaggaag  
241 gtcattggcc agcaaaaggg tctctgaatc tgtgaaggcc ttgctgttaa agggcaaaag  
301 tcctgtggac ccagagtgtg cagccaaggt ggggaaggct catgtgtatt gtgaaggaaa  
361 tgatgtctat gatgtcatgc taaatcagac caatctccag ttcaacaaca acaagtacta  
421 tctgattcag ctattagaag atgatgccca gaggaacttc agtgtttgga tgagatgggg  
481 ccgagttggg aaaatgggac agcacagcct ggtggcttgt tcaggcaatc tcaacaaggc  
541 caaggaaatc ttccagaaga aattccttga caaacgaaa aacaattggg aagatcgaga  
601 aaagtttgag aaggtgcctg gaaaatatga tatgctacag atggactatg ccaccaatac  
661 tcaggatgaa gaggaacaa aaaaagagga atctctaaa tctcccttga agccagatc  
721 acagctagat ctccgggtac aggagttaat aaagttgatc tgtaatgttc aggccatgga  
781 agaaatgatg atggaaatga agtataatac caagaaagcc ccacttgga agctgacagt  
841 ggcacaaatc aaggcaggtt accagtctct taagaagatt gaggattgta ttcgggctgg  
901 ccagcatgga cgagctctca tggaagcatg caatgaatc tacaccagga ttccgcatga  
961 ctttgactc cgtactctc cactaatccg gacacagaag gaactgtcag aaaaaataca  
1021 attactagag gctttgggag acattgaaat tgctattaag ctggtgaaa cagagctaca  
1081 aagcccagaa caccattgg accaacata tagaaaccta catttgtcct tgcgccccct  
1141 tgacctgaa agttacgagt tcaaagtgat ttccagtac ctacaatcta cccatgtcc  
1201 cacacacagc gactatacca tgaccttgct ggatttgtt gaagtggaga aggatggtga  
1261 gaaagaagcc ttcagagagg acctcataa caggatgctt ctatggcatg gtccaggat  
1321 gagtaactgg gtgggaatct tgagccatgg gcttcgaatt gccaccctg aagctccat  
1381 cacaggttac atgtttggga aaggaatcta ctttgctgac atgtcttcca agagtgccaa  
1441 ttactgctt gcctctgcc taaagaatac aggactgctg ctcttatcag aggtagctct  
1501 aggtcagtgt aatgaactac tagaggccaa tctaaggcc gaaggattgc ttcaaggtaa  
1561 acatagcacc aaggggctgg gcaagatggc tcccagttct gccacttcg tcaccctgaa  
1621 tgggagtaca gtgccattag gaccagcaag tgacacagga attctgaatc cagatggta  
1681 taccctcaac tacaatgaat atattgtata taacccaac caggtccgta tgcggtacct  
1741 tttaaagggt cagtttaatt tccttcagct gtggtgaatg ttgatcttaa ataaaccaga  
1801 gatctgatct tcaagcaaga aaataagcag tgttgactt gtgaattttg tgatatttta  
1861 tgtaataaaa actgtacagg tctaaaaaaa aaaaaaaaaa aaaaaaaaaa

//

Figure 11

1 tgggactggt cgcctgactc ggccctgcccc agcctctgct tcacccact ggtggccaaa  
61 tagccgatgt ctaatcccc acacaagctc atccccggcc tctgggattg ttgggaattc  
121 tctcccta at tcacgcctga ggctcatgga gagttgctag acctgggact gccctgggag  
181 gcgcacacaa ccaggccggg tggcagccag gacctctccc atgtccctgc ttctctggc  
241 catggctcca aagccgaagc cctgggtaca gactgagggc cctgagaaga agaagggccg  
301 gcaggcagga agggaggagg accccttccg ctccaccgct gaggccctca aggccatacc  
361 cgcagagaag cgcataatcc gcgtggatcc aacatgtcca ctacagcaga acccgggac  
421 ccaggtgtat gaggactaca actgcaccct gaaccagacc aacatcgaga acaacaacaa  
481 caagtctac atcatccagc tgctccaaga cagcaaccgc ttcttcacct gctggaaccg  
541 ctggggccgt gtgggagagg tggccagtc aaagatcaac cacttcacaa ggctagaaga  
601 tgcaagaag gacttgaga agaaatttcg ggaaaagacc aagaacaact gggcagagcg  
661 ggaccacttt gtgtctcacc cgggcaagta cacacttacc gaagtacagg cagaggatga  
721 ggcccaggaa gctgtggtga aggtggacag agggccagtg aggactgtga ctaagcgggt  
781 gcagccctgc tcctggacc cagccagca gaagctcacc actaacatct tcagcaagga  
841 gatgttcaag aacaccatgg ccctcatgga cctggatgtg aagaagatgc ccctgggaaa  
901 gctgagcaag caacagattg cacggggtt cgaggcctg gaggcgctgg aggaggccct  
961 gaaaggcccc acggatggtg gccaaagcct ggaggagctg tcctcacact ttacaccgt  
1021 catccgcac aactcggcc acagccagcc cccgccacc aattcccctg agcttctgca  
1081 ggccaagaag gacatgctgc tgggtctggc ggacatcgag ctggcccagg ccctgcaggc  
1141 agtctctgag caggagaaga cggtgaggga ggtgccacac ccctggacc gagactacca  
1201 gcttctcaag tgccagctgc agctgctaga ctctggagca cctgagtaca aggtgataca  
1261 gacctactta gaacagactg gcagcaacca caggtgccct acactcaac acatcggaa  
1321 agtaaaccaa gaaggggagg aagacagatt ccaggccac tccaaactgg gtaatcgga  
1381 gctgctgtgg catggacca acatggccgt ggtggccgcc atcctacta gtgggctccg  
1441 catcatgcca cattctggtg ggcgtgttg caagggcacc tactttgcct cagagaacag  
1501 caagtcagct ggatatgta ttggcatgaa gtgtggggcc caccatgtcg gctacatgtt  
1561 cctgggtgag gtggccctgg gcagagagca ccatatcaac acggacaacc ccagcttgaa  
1621 gagccacct cctggcttcg acagtgtcat tgcccaggc cacaccgagc ctgatccgac  
1681 ccaggacact gaggtaggc tggatggcca gcaagtgtg gtgcccagg gccagcctgt  
1741 gccctgcca gaggtagca gctccacatt ctcccagagc gactacctca tctaccagga  
1801 gagccagtgt cgcctgcgt acctgctgga ggtccacctc tgagtcccc ccctgtcccc  
1861 cggggtcctg caaggctgga ctgtgatct caatcatcct gccatctct ggtacccta  
1921 taccactcct tttttcaag aatacaatc gtgtgtgta actatagtc ccatgctgta  
1981 caagatccct gaacttatgc ctctaactg aaatttgta ttcttgaca catctgcca  
2041 gtccctctcc tcccagcca tgtaaccag catttgactc ttacttgta taagggcagc  
2101 tttataggt tccatgta agtgagatca tgcagtgtt gtcttctgt gcctggctta  
2161 ttactcag cataatgtc accgggttca ccatgttt cataaatgac aagattcct  
2221 ctttaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaa

Figure 12

14/20

```

1  cgaagatggc  ggcgtcgcgt  cgctctcagc  atcatcacca  ccatcatcaa  caacagctcc
61  agcccccccc  aggggcttca  gcgcgcgcgc  cgccacctcc  tccccactc  agccctggcc
121  tggccccggg  gaccacccca  gcctctccca  cggccagcgg  cctggcccc  ttgcctccc
181  cgcggcacgg  cctagcgcgt  ccggaggggg  atggcagtcg  ggatccgccc  gacaggcccc
241  gatccccgga  cccggttgac  ggtaccagct  gttgcagtac  caccagcaca  atctgtaccg
301  tcgcccgcgc  tcccgtggtc  ccagcgggtt  ctacttcac  tgccgctggg  gtcgctccca
361  acccagccgg  cagtggcagt  aacaattcac  cgtcgtcctc  ttcttcccc  acttcttct
421  catcttcttc  tccatcctcc  cctggatcga  gcttggcgga  gagccccgag  gcggccggag
481  ttagcagcac  agcaccactg  gggcctgggg  cagcaggacc  tgggacaggg  gtcccagcag
541  tgagcggggc  cctacgggaa  ctgctggagg  cctgtcgcaa  tggggacgtg  tcccggttaa
601  agaggctggg  ggacgcggca  aacgtaaatg  caaaggacat  ggccggccgg  aagtcttctc
661  ccctgcactt  cgctgcaggt  tttggaagga  aggatgttgt  agaacactta  ctacagatgg
721  gtgctaattg  ccacgctcgt  gatgatggag  gtctcatccc  gcttcataat  gctgttctt
781  ttggccatgc  tgaggttggt  agtctgttat  tgtgccaagg  agctgatcca  aatgccaggg
841  ataactggaa  ctatacacct  ctgcatgaag  ctgctattaa  agggaagatc  gatgtgtgca
901  ttgtgctgct  gcagcacgga  gctgacccaa  acattcgga  cactgatggg  aaatcagccc
961  tggacctggc  agatccttca  gcaaaagctg  tccttacagg  tgaatacaag  aaagacgaac
1021  tcctagaagc  tgctaggagt  ggtaatgaag  aaaaactaat  ggctttactg  actcctctaa
1081  atgtgaattg  ccatgcaagt  gatgggcgaa  agtcgactcc  ttacatctca  gcagcgggct
1141  acaacagagt  tcgaatagtt  cagcttcttc  ttcagcatgg  tgctgatgtt  catgcaaaag
1201  acaaaggtgg  acttgtgcct  cttcataatg  catgttcata  tggacattat  gaagtccag
1261  aactgctact  aaagcatgga  gcttgtgtta  atgccatgga  tctctggcag  ttactccac
1321  tgcacgaggg  tgcttccaag  aaccgtgtag  aagtctgctc  tttgttactt  agccatggcg
1381  ctgatcctac  gttagtcaac  tgccatggca  aaagtgtgtg  ggatatggct  ccaactccgg
1441  agcttaggga  gagattgact  tatgaattta  aaggtcattc  ttactacaa  gcagccagag
1501  aagcagactt  agctaaagt  aaaaaaacac  tcgctctgga  aatcattaat  ttcaaacac
1561  cgcagtctca  tgaaacagca  ctgcactgtg  ctgtggcctc  tctgcatccc  aaacgtaaac
1621  aagtgcagaa  attgttactt  agaaaaggag  caaatgttaa  tgaaaaaat  aaagatttca
1681  tgactccctc  gcatgttgca  gccgaaagag  ccataatga  tgtcatggaa  gttctgcata
1741  agcatggcgc  caagatgaat  gcactggaca  cccttggtca  gactgtcttg  catagaccgg
1801  ccctagcagg  ccacctgcag  acctgccgcc  tctgtctgag  ttacggctct  gacccctcca
1861  tcatctcctt  acaaggcttc  acagcagcac  agatgggcaa  tgaagcagt  cagcagattc
1921  tgagtgtgag  ttacggctct  gacccctcca  tcatctcctt  acaaggcttc  acagcagcac
1981  agatgggcaa  tgaagcagt  cagcagattc  tgagtgttca  ttcgtagata  gtgatcattc
2041  tacttcaagg  ttaatggtga  tcttgagacg  ggaagattta  gaaggaaatc  tatccagcat
2101  gtcttctact  tcaacatgaa  gagtacacct  atacgtactt  ctgatgttga  ttatcgactc
2161  ttagaggcat  ctaaagctgg  agacttgga  actgtgaagc  aactttgcag  ctctcaaaat
2221  gtgaattgta  gagacttaga  gggccggcat  tccacgccct  tacacttcgc  agcaggctac
2281  aacagagtac  acctatacgt  acttctgatg  ttgattatcg  actcttagag  gcatctaaag
2341  ctggagactt  ggaactgtg  aagcaacttt  gcagctctca  aaatgtgaat  tgtagagact
2401  tagaggccgg  gcattccacg  cccttacact  tcgcagcagg  ctacaaccgc  gtgtctgttg
2461  tagagtacct  gctacaccac  ggtgccgatg  tccatgccaa  agacaagggt  ggcttggtgc
2521  cccttcataa  tgcctgttca  tatggacact  atgaggtggc  tgagctttta  gtaaggcatg
2581  gggcttctgt  caatgtggcg  gacttatgga  aatttaccct  tctccatgaa  gcagcagcta
2641  aaggaaagta  tgaaatctgc  aagctccttt  taaaacatgg  agcagatcca  actaaaaaga
2701  acagagatgg  aaatacacct  ttggatttgg  taaaggaagg  agacacagat  attcaggact
2761  tactgaaagg  ggatgctgct  ttgttgatg  ctgccaagaa  gggctgcctg  gcaagagtgc
2821  agaagctctg  taccacagag  aatatcaact  gcagagacac  ccagggcaga  aattcaacc
2881  ctctgcacct  ggcagcaggc  tataataacc  tggaagtagc  tgaatatctt  ctagagcatg
2941  gagctgatgt  taatgcccg  gacaagggtg  gtttaattcc  tcttcataat  gcggcatctt
3001  atgggcatgt  tgacatagcg  gctttattga  taaaatacaa  cactgtgtga  aatgcaacag
3061  ataagtgggc  gtttactccc  ctccatgaag  cagcccagaa  aggaaggacg  cagctgtgcg
3121  ccctcctcct  agcgcattgg  gcagacccca  ccatgaagaa  ccagggaagg  cagacgcctc
3181  tggatctggc  aacagctgac  gatatcagag  ctttgctgat  agatgccatg  cccccaggg
3241  ccttacctac  ctgttttaaa  cctcaggcta  ctgtagttag  tgctctctg  atctcaccag
3301  catccacccc  ctctgcctc  tcggctgcca  gcagcataga  caacctcact  ggccctttag
3361  cagagtggc  cgtaggagga  gcctccaatg  caggggatgg  cgccgcggga  acagaaagga
3421  aggaaggaga  agttgctggg  cttgacatga  atatcagcca  atttctaaaa  agccttggcc
3481  ttgaacacct  tcgggatata  tttgaaacag  aacagattac  actagatgtg  ttggctgata
3541  tgggtcatga  agagtggaaa  gaaataggca  tcaatgcata  tgggcaccgc  cacaatttaa
3601  tcaaaggagt  agaaagactc  ttaggtggac  aacaaggcac  caatccttat  ttgacttttc
3661  actgtgttaa  tcagggaacg  atttgtctgg  atcttgctcc  agaagataaa  gaatatcagt
3721  cagtggaga  agagatgcaa  agtactatc  gagaacacag  agatgggtgt  aatgctggcg
3781  gcatcttcaa  cagatacaat  gtcattcgaa  ttcaaaaagt  tgtcaacaag  aagttagggg
3841  agcggttctg  ccaccgacag  aaggaaagtgt  ctgaggagaa  tcacaaccat  cacaatgagc

```

3901 gcatgttggt tcatggttct cctttcatta atgccattat tcataaaggg tttgatgagc  
3961 gacatgcata cataggagga atgtttgggg ccgggattta ttttgctgaa aactcctcaa  
4021 aaagcaacca atatgtttat ggaattggag gaggaacagg ctgccctaca cacaaggaca  
4081 ggtcatgcta tatatgtcac agacaaatgc tcttctgtag agtgaccctt gggaaatcct  
4141 ttctgcagtt tagcaccatg aaaatggccc acgcgcctcc agggcaccac tcagtcattg  
4201 gtagaccgag cgtcaatggg ctggcatatg ctgaatatgt catctacaga ggagaacagg  
4261 catacccaga gtatcttata acttaccaga tcatgaagcc agaagcccct tcccagaccg  
4321 caacagccgc agagcagaag acctagttaa tgcctgctgg tgaaggccag atcagatttc  
4381 aacctgggac tggattacag aggattgttt ctaataacaa catcaatatt ctagaagtcc  
4441 ctgacagcct agaaataagc tgtttgtctt ctataaagca ttgctatagt g

Figure 13

1 cgcgccgcct cgctagccga aacctgccca gccggtgccc ggccactgcg cacgcgcggg  
 61 acgacgtcac gtgcgtccc ggggctggac ggagctggca ggaggggcct tgccagcttc  
 121 cgccgccgcg tcgttcagg acccgacgg cggttcgcg ctgcctccgc cgccgcgggg  
 181 cagccggggg gcagggagcc cagcgagggg cgcgcgtggg cgcggccatg ggactgcgcc  
 241 ggatccggtg acagcaggga gccaagcggc ccgggccctg agcgcgtctt ctccgggggg  
 301 cctcgccctc ctgctcggg ggccggggct cctgctccgg ttgctggcgc tgttctggc  
 361 tgtggcggcg gccaggatca tgtcgggtcg ccgtgcgcc ggccgggggag cggcctgcgc  
 421 gagcgccgcg gccgagggcg tggagccggc cggccgagag ctgttcgagg cgtgccgcaa  
 481 cggggacgtg gaacgagtca agaggctggt gacgcctgag aaggtgaaca gccgcgacac  
 541 ggcgggcagg aatccaccc cgctgcactt cgccgcaggt ttggggcgga aagacgtagt  
 601 tgaatattg ctccagaatg gtgcaaatgt ccaagcacgt gatgatgggg gccttatcc  
 661 tctcataat gcattctctt ttggtcatgc tgaagtagtc aatctcttt tgcgacatgg  
 721 tgcagacccc aatgctcgag ataattggaa ttatactcct ctccatgaag ctgcaattaa  
 781 aggaaagatt gatgtttgca ttgtgctgtt acagcatgga gctgagccaa ccatccgaaa  
 841 tacagatgga aggacagcat tggatttagc agatccatct gccaagcag tgcttactgg  
 901 tgaatataag aaagatgaac tcttagaaag tgccaggagt ggcaatgaag aaaaaatgat  
 961 ggctctactc acaccattaa atgtcaactg ccacgcaagt gatggcagaa agtcaactcc  
 1021 attacattg gcagcaggat ataacagagt aaagattgta cagctgttac tgcaacatgg  
 1081 agctgatgtc catgctaaag ataaagggtga tctggtacca ttacacaatg cctgttctta  
 1141 tggctattat gaagtaactg aacttttggg caagcatggt gcctgtgtaa atgcaatgga  
 1201 ctgttgcaa ttcactctc tcatgaggc agcttctaag aacagggttg aagtatgttc  
 1261 tcttctctta agttatggtg cagacccaac actgctcaat tgcacaata aaagtgtat  
 1321 agacttggtc cccacaccac agttaaaga aagattagca tatgaattta aaggccactc  
 1381 gttgctgcaa gctgcacgag aagctgatgt tactcgaatc aaaaaacatc tctcttgga  
 1441 aatggtgaat ttcaagcatc ctcaaacaca tgaacagca ttgcattgtg ctgctgcac  
 1501 tccatatccc aaaagaaagc aaatatgtga actgttgcta agaaaaggag caaacatcaa  
 1561 tgaagagact aaagaattct tgactcctct gcacgtggca tctgagaaaag ctcataatga  
 1621 tgtgttgtaa gtagtggtga aacatgaagc aaaggtaat gctctggata atcttggtca  
 1681 gacttctcta cacagagctg catattgtgg tcatctacaa acctgccgcc tactctgag  
 1741 ctatgggtgt gactctaaca ttatatccct tcagggcttt actgctttac agatgggaaa  
 1801 tgaaaatgta cagcaactcc tccaagaggg tatctcatta ggtaattcag aggcagacag  
 1861 acaattgctg gaagctgcaa aggctggaga tgcgaaact gtaaaaaaac tgtgtactgt  
 1921 tcagagtgtc aactgcagag acattgaagg gcgtcagtct acaccacttc atttgcagc  
 1981 tgggtataac agagtgtccg tgggtgaata tctgtacag catggagctg atgtgcatgc  
 2041 taaagataaa ggaggccttg tacctttgca caatgcatgt tcttatggac attatgaagt  
 2101 tgcagaactt ctgtttaaac atggagcagt agttaatgta gctgatttat ggaaatttac  
 2161 acctttacat gaagcagcag caaaaggaaa atatgaaatt tgcaaaacttc tgcctcagca  
 2221 tgggtcagac cctacaaaaa aaaacaggga tggaaatact cctttggatc ttgttaaaga  
 2281 tggagataca gatattcaag atctgcttag gggagatgca gctttgctag atgctgcaa  
 2341 gaagggtgt ttgccagag tgaagaagtt gtcttctcct gataatgtaa attgccgcga  
 2401 taccaaggc agacattcaa cacctttaca tttagcagct ggttataata attagaagt  
 2461 tgcagagtat ttgtacaac acggagctga tgtgaatgcc caagacaaag gaggacttat  
 2521 tctttacat aatgcagcat ctacgggca ttagatgta gcagctctac taataaagta  
 2581 taatgcatgt gtcaatgcca cggacaaatg ggctttcaca cctttgcacg aagcagccca  
 2641 aaagggacga acacagcttt gtgctttggt gctagcccat ggagctgacc cgactcttaa  
 2701 aatcaggaa ggacaaacac cttagattt agtttcagca gatgatgtca gcgctctct  
 2761 gacagcagcc atgcccccat ctgctctgcc ctctgttac aagcctcaag tgctcaatgg

2821 tgtgagaagc ccaggagcca ctgcagatgc tctctcttca ggtccatcta gccatcaag  
2881 cctttctgca gccagcagtc ttgacaactt atctgggagt tttcagaac tgtcttcagt  
2941 agttagtcca agtggaaacag aggggtgcttc cagtttgag aaaaaggagg ttccaggagt  
3001 agattttagc ataactcaat tcgtaaggaa tcttggaact gagcacctaa tggatatatt  
3061 tgagagagaa cagatcactt tggatgtatt agttgagatg gggcacaagg agctgaagga  
3121 gattggaatc aatgcttatg gacataggca caaactaatt aaaggagtcg agagacttat  
3181 ctccggacaa caaggtctta acccatattt aactttgaac acctctggtg gtggaacaat  
3241 tcttatagat ctgtctcctg atgataaaga gtttcagtct gtggaggaag agatgcaaa  
3301 tacagttcca gagcacagag atggaggtca tgcagggtga atcttcaaca gatacaatat  
3361 tctcaagatt cagaagggtt gtaacaagaa actatgggaa agatacactc accggagaaa  
3421 agaagtttct gaagaaaacc acaaccatgc caatgaacga atgctatttc atgggtctcc  
3481 tttgtgaat gcaattatcc acaaaggctt tgatgaaagg catgcgtaca taggtggtat  
3541 gtttgagct ggcatttatt ttgctgaaaa ctcttccaaa agcaatcaat atgtatatgg  
3601 aattggagga ggtactgggt gtccagtcca caaagacaga tcttggtaca ttgccacag  
3661 gcagctgctc tttgccggg taaccttggg aaagtcttc ctgcagtcca gtgcaatgaa  
3721 aatggcacat tctctccag gtcactactc agtactggt aggccagtg taaatggcct  
3781 agcattagct gaatatgta ttacagagg agaacaggct tctctgagt atttaattac  
3841 ttaccagatt atgaggcctg aaggtatggt cgatggataa atagtattt taagaaacta  
3901 attccactga acctaaaac atcaaagcag cagtggcctc tacgttttac tctttgctg  
3961 aaaaaaatc atcttgcca caggcctgtg gcaaaaggat aaaaatgtga acgaagtta  
4021 acattctgac ttgataaagc ttaataatg tacagtgtt tctaaatatt tctgtttt  
4081 tcagcacttt aacagatgcc attccaggtt aaactgggtt gtctgtacta aattataaac  
4141 agagttaact tgaacctttt atatgtatg cattgattct aacaaactgt aatgccctca  
4201 acagaactaa tttactaat acaatactgt gttctttaa acacagcatt tacactgaat  
4261 acaatttcat ttgtaaaact gtaataaga gctttgtac tagcccagta ttatttaca  
4321 ttgctttgta atataaatct gttttagaac tgcagcgggt tacaaaattt tttcatatgt  
4381 attgttcac tatacttcat cttacatcgt catgattgag tgatctttac atttgattcc  
4441 agaggctatg ttcagttggt agttgggaaa gattgagta tcagatttaa ttgccgatg  
4501 ggagccttta tctgtcatta gaaatcttc tcatttaaga acttatgaat atgctgaaga  
4561 tttatttgt gataccttg tatgtatgag acacattcca aagagctcta actatgatag  
4621 gtcttgatta ctaaagaagc ttcttactg gctcaattt ctagcttcca tgttgaaaa  
4681 tttctgcag tcttctgtg aaaattagag caaagtgtc ctgttttta gagaaactaa  
4741 atcttctgt tgaacaatta ttgtgtctt tcatggaac ataagtagga tgtaacatt  
4801 tccagggtgg gaagggtaat cctaaatcat tcccaatct attctaata cctaaatct  
4861 aaaggggaaa aaaaaatca caaacaggac tgggtagttt ttatcctaa gtatatttt  
4921 tctgttctt ttacttgggt ttattgctg tatttatagc caatctatac atcatgggt  
4981 aacttaacc agaactataa aatgtagtgt ttcagtccc ctccaggcct cctgaatggg  
5041 caagtgcagt gaaacaggtg ctctctgtc ctgggtttc tctccatgat gttatgcca  
5101 attgaaata tgctgtcagt ttgtgcacca tatggtgacc acgcctgtgc tcagttggc  
5161 agctatagaa ggaaatgctg tccataaaa tgccatccct atttctaata taacactct  
5221 tccaggaag catgcttaag catcttgta cagagacata catccattat ggcttgga  
5281 tctctttat ttgtgactc tagtccctt caaagtcgag gaaagatctt tactactta  
5341 atgaggacat tccccatcac tgtctgtacc agttcacctt tattttacgt ttattcagt  
5401 ctgtaaatta actggccctt tgcagtaact tgtacataaa gtgctagaaa atcatgtcc  
5461 ttgtctgag taagagttaa tcagagtaag tgcattctg gattgtttc tgtgatgaa  
5521 attatgatca ttatttaaga agtcaaatcc tgatcttgaa gtgctttta tacagctctc  
5581 taataattac aaatatccga aagtcattc ttggaacaca agtggagtat gccaaattt  
5641 atatgaattt tcagattat ctaagctcc aggtttata attagaagat aatgagagaa  
5701 ttaatgggtt ttattttac attatctctc aactatgtag cccatattac tcaccctatg  
5761 agtgaatctg gaattgctt tcatgtgaaa tcattgtggt ctatgagttt acaactactc

5821 aaactgtgtt attttatcta aaccattgct taatgagtgt gttttccat gaatgaatat  
5881 accgtgggtc atatgttagc atggcagcat ttccagatag cttttgttt gttgggaagt  
5941 tgggggtttg gggggagggg gagtattagt acgttgcacg gaatagccta ctttataatg  
6001 atgggaatgc tttttctttt gttttgggat tttttttt gaagtgaaat ttaactttt  
6061 gtgccagtag tactattata cccatcttca gtgtcttact tgtactgtat caaattccat  
6121 accctcattt aattcttaat aaaactgttc acttgtaaaa aaaaaaaaaa aaaaaaaaaa  
6181 aaaaaaaaaa

Figure 14

1 cgcccgccca gccccggggg cagggaagc ctaaattacg gaattaccgc gagcaaggag  
61 cgcggaatcg gggagcgtcc ggagctagct ggatcctcta ggcaggatgg tgatgggaat  
121 ctttgcaaat tgtatcttct gtttgaaagt gaagtactta cctcagcagc agaagaaaaa  
181 gctacaaact gacattaagg aaaatggcgg aaagttttcc ttttcgttaa atcctcagt  
241 cacacatata atcttagata atgctgatgt tctgagtcag taccaactga attctatcca  
301 aaagaaccac gtcatattg caaaccaga ttttatatgg aaatctatca gagaaaagag  
361 actcttggat gtaaagaatt atgacctta taagcccctg gacatcacac cacctcctga  
421 tcagaaggcg agcagttctg aagtgaaac agaaggtcta tgcccgga gtgccacaga  
481 ggaggaagac actgtggaac tactgagtt tggtatgcag aatgttga ttcctcatct  
541 tctcaagat tttgaagtg caaaatataa caccttggag aaagtgggaa tggaggagg  
601 ccaggaagct gtggtggtg agcttcagt ttcgcgggac tccagggact gtccttct  
661 gatatactca cacttctcc tggatgatgg catggagact agaagacagt ttgctataaa  
721 gaaaacctct gaagatgcaa gtgaatactt tgaataatc attgaagaac tgaagaaaca  
781 aggatttcta ctaagagaac attcacacc tgaagcaacc caattagcat ctgaacaatt  
841 gcaagcattg cttttggagg aagtcatgaa ttcaagcact ctgagccaag aggtgagcga  
901 tttagtagag atgatttggg cagaggccct gggccacctg gaacacatgc ttctcaagcc  
961 agtgaacagg attagcctca acgatgtgag caaggcagag gggattctcc ttctagtaaa  
1021 ggcagcactg aaaaatggag aaacagcaga gcaattgcaa aagatgatga cagagtttta  
1081 cagactgata cctcacaag gcacaatgcc caaagaagt aacctgggac tattggctaa  
1141 gaaagcagac ctctgccagc taataagaga catggttaat gtctgtgaaa ctaatttgc  
1201 caaacccaac ccaccatccc tggccaataa ccgagctttg aggtgcaaaa ttgagcatgt  
1261 tgaacagaat actgaagaat ttctcagggt tagaaaagag gtttgcaga atcatcacag  
1321 taagagccca gtggatgtct tgcagatatt tagagttggc agagtgaatg aaaccacaga  
1381 gtttttgagc aaacttggt atgtgaggcc cttgttgcg gtttctctg tacaaaacat  
1441 cgtgggaatc ttgtgtcag ggttgccttt acccaaagta gtggaagatc gtggtgtgca  
1501 aagaacagac gtcggaaacc ttggaagtgg gatttattc agtgattcgc tcagtacaag  
1561 tatcaagtac tcacaccgg gagagacaga tggcaccaga ctctgctca tttgtgacgt  
1621 agccctcgga aagtgtatgg acttacatga gaaggacttt ccctaactg aagcaccacc  
1681 aggctacgac agtgtgcatg gatttcaca aacagcctct gtcaccacag actttgagga  
1741 tgatgaattt gttgtctata aaaccaatca ggftaaatg aaatatatta ttaaatttc  
1801 catgcctgga gatcagataa aggacttca tctagtgtat catactgaat tagaggaata  
1861 cagacctgag tttcaaatt tttcaaagg tgaagattac cagttaccag atgcaaaac  
1921 ttccagcagc accaaggccg gcctccagga tgctctggg aacttggtc ctctggagga  
1981 tgtccacatc aaaggagaa tcatagacac ttagcccag gtcattgtt ttcacacata  
2041 cacaataaa agtcacgtgc ccattgagc aaaatatatc tttccttgg atgacaaggc  
2101 cgtgtgtgt ggcttgaag cttcatcaa tgggaagcac atagttggag agattaaaga  
2161 gaaggaagaa gccagcaag agtacctaga agcgtgacc cagggccatg gcgcttacct  
2221 gatgagtcag gatgtccgg acgttttac tgtaagtgtt ggaacttac ccctaaggc  
2281 taaggttctt ataaaaatta cctacatcac agaactcagc atcctgggca ctgttggtgt  
2341 cttttcatg cccgccaccg tagcaccctg gcaacaggac aaggcttga atgaaaacct  
2401 tcaggatata gtagagaaga tttgtataaa agaaatagga acaaaagaaa gcttctctt  
2461 gactatgtct attgagatgc cgtatgtgat tgaattcatt ttcagtata cacatgaact  
2521 gaaacaaaag cgcacagact gcaaagctgt cattagcacc atggaaggca gtccttaga  
2581 cagcagtgga ttttctcc acatcggtt gtctgtgcc tatctccaa gaatgtgggt  
2641 tgaaaaacat ccagaaaaag aaagcgaggc ttgcatgctt gtcttcaac ccgatctcga  
2701 tgcgacctc cctgacctag ccagtgagag cgaagtgaatt attgtcttg actgctccag

2761 ttccatggag ggtgtgacat tcttgcaagc caagcaaadc accttgcacg cgctgtcctt  
2821 ggtgggtgag aagcagaaag taaatattat ccagttcggc acaggttaca aggagctatt  
2881 ttcgtatcct aagcatatca caagcaatac cagggcagca gagttcatca tgtctgccac  
2941 acctaccatg gggaacacag acttctggaa aacactccga tatcttagct tattgtaccc  
3001 tgctcgaggg tcacggaaca tcctcctggt gtctgatggg cacctccagg atgagagcct  
3061 gacattacag ctcgtgaaga ggagccgccc gcacaccagg ttattcgcct gcggtatcgg  
3121 ttctacagca aatcgtcacg tcttaaggat ttgtcccag tgtggtgccg gagtatttga  
3181 atattttaat gcaaaatcca agcatagtgt gagaaaacag atagaagacc aaatgaccag  
3241 gctatgttct ccgagttgcc actctgtctc cgtcaaatgg cagcaactca atccagatgc  
3301 gcccagagcc ctgcaggccc cagcccaggt gccatccttg ttctgcaatg atcgactcct  
3361 tgtctatgga ttatttctc actgcacaca agcaactctg tgtgcactaa ttcaagagaa  
3421 agaattttgt acaatggtgt cgactactga gcttcagaag acaactggaa ctatgatcca  
3481 caagctggca gcccagctc taatcagaga ttatgaagat ggcattcttc acgaaaatga  
3541 aaccagtcac gagatgaaaa aacaaactt gaaatctctg attattaaac tcagtaaaga  
3601 aaactctctc ataacacaat ttacaagctt tgtggcagtt gagaaaaggg atgagaatga  
3661 gtgcctttt cctgatattc caaaagtctc tgaacttatt gccaaagaag atgtagactt  
3721 cctgccctac atgagctggc agggggagcc ccaagaagcc gtcaggaacc agtctctttt  
3781 agcatcctct gagtggccag aattacgttt atccaaacga aaacatagga aaattccatt  
3841 ttccaaaaga aaaatggaat tatctcagcc agaagttct gaagatttg aagaggatgg  
3901 cttaggtgta ctaccagctt tcacatcaaa ttggaacgt ggaggtgtgg aaaagctatt  
3961 ggatttaagt tggacagagt catgtaaac aacagcaact gaaccactat ttaagaaagt  
4021 cagtccatgg gaaacatcta ctctagctt ttctctatt ttggctccgg ccgttggttc  
4081 ctatcttacc ccgactaccc gcgtcacag tctgtctcc ttgtctttg cctcatatcg  
4141 tcaggtagct agtttcggtt cagctgtctc tcccagacag ttgatgcat ctcaattcag  
4201 ccaaggccct gtgcctggca cttgtgtga ctggatccca cagtcggcgt cttgtccac  
4261 aggacctccc cagaaccac cttctgcacc ctattgtggc attgttttt caggagctc  
4321 attaagctct gcacagtctg ctccactgca acatcctgga ggctttacta ccaggccttc  
4381 tgctggcacc ttccctgagc tggattctcc ccagcttcat ttctctctc ctacagacc  
4441 tgatcccatc agaggtttg ggtcttatca tccctctgct tactctcctt ttcatttca  
4501 accttccgca gcctctttga ctgccaacct taggctgcca atggcctctg ctttacctga  
4561 ggctctttgc agtcagtccc ggactacccc agtagatctc tgtctctag aagaatcagt  
4621 aggcagtctc gaaggaagtc gatgcctgt cttgtcttt caaagttctg acacagaaag  
4681 tgatgagcta tcagaagtac ttcaagacag ctgctttta caaataaagt gtgatacaaa  
4741 agatgacagt atcccgtgct ttctggaatt aaaagaagag gatgaaatag tgtgcacaca  
4801 acactggcag gatgctgtgc cttggacaga actcctcagt ctacagacag aggatggctt  
4861 ctggaaactt acaccagaac tgggacttat attaaatctt aatacaaatg gtttgacag  
4921 ctttcttaaa caaaaaggca ttcaatctct aggtgtaaaa ggaagagaat gtctcctgga  
4981 cctaattgcc acaatgctgg tactacagtt tattcgcacc aggttggaag aagagggaat  
5041 agtgttcaaa tcaatgatga aaatggatga ccttctatt tccaggaata ttccctgggc  
5101 ttttgaggca ataaagcaag caagtgaatg ggtaagaaga actgaaggac agtaccatc  
5161 tatctgccc cggcttgaac tggggaacga ctgggactct gccaccaagc agttgtctgg  
5221 actccagccc ataagcactg tgtccctct tcatagagtc ctccattaca gtcaaggcta  
5281 agtcaaatga aactgaattt taaactttt gcattgctt atgtagaaaa taatcaaatg  
5341 ataatagata attataatga aacttcatta aggtttcatt cagtgtagca attactgtct  
5401 ttaaaaatta agtgaagaa gaattacttt aatcaactaa caagcaataa taaaatgaaa  
5461 cttaaaataa aaaaaaaaaa aaaaaaaaaa

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB2004/003235

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/11 A61K38/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, Sequence Search, CHEM ABS Data, EMBASE, WPI Data, PAJ

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	MASSUDA EDMOND ET AL: "GPI 6150, a PARP inhibitor, down-regulates metastasis associated S100A4 (Mts1) and suppresses invasion of breast cancer cells in vitro." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 44, July 2003 (2003-07), pages 867-868, XP001181719 & 94TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; WASHINGTON, DC, USA; JULY 11-14, 2003 ISSN: 0197-016X abstract	1-5, 11-32
X	WO 02/12239 A (BOLKENIUS FRANK ; SANOFI SYNTHELABO (FR); BARTH FRANCIS (FR); BICHON D) 14 February 2002 (2002-02-14) claims	1-5, 11-32
	----- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

18 November 2004

Date of mailing of the international search report

01/12/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Didelon, F

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/003235

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/24379 A (CALVERT ALAN HILARY ; CANCER RES CAMPAIGN TECH (GB); CURTIN NICOLA JAN) 14 September 1995 (1995-09-14) claims	1-5, 11-32
X	----- WELTIN D ET AL: "EFFECT OF 6(5H)-PHENANTHRIDINONE, AN INHIBITOR OF POLY(ADP-RIBOS) POLYMERASE, ON CULTURED TUMOR CELLS" ONCOLOGY RESEARCH, PERGAMON PRESS, NEW YORK, NY, US, vol. 6, no. 9, 1994, pages 399-403, XP008003298 ISSN: 0965-0407 abstract	1-5, 11-32
P,Y	----- SCHULTZ NIKLAS ET AL: "Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination." NUCLEIC ACIDS RESEARCH, vol. 31, no. 17, 1 September 2003 (2003-09-01), pages 4959-4964, XP002305998 ISSN: 0305-1048 the whole document	1-32
Y	----- LARMINAT FLORENCE ET AL: "Deficiency in BRCA2 leads to increase in non-conservative homologous recombination" ONCOGENE, vol. 21, no. 33, 1 August 2002 (2002-08-01), pages 5188-5192, XP002305999 ISSN: 0950-9232 the whole document	1-32
A	----- SHALL SYDNEY ET AL: "Poly (ADP-ribose) polymerase-1: What have we learned from the deficient mouse model?" MUTATION RESEARCH, vol. 460, no. 1, 30 June 2000 (2000-06-30), pages 1-15, XP002306000 ISSN: 0027-5107 the whole document	1-32
A	----- DATABASE EMBL 23 March 2001 (2001-03-23), STRAUSBERG, R.: XP002306001 retrieved from EBI Database accession no. BG483078 abstract	8
	----- -/--	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB2004/003235

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>ELBASHIR SAYDA M ET AL: "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 411, no. 6836, 24 May 2001 (2001-05-24), pages 494-498, XP002206451 ISSN: 0028-0836 the whole document</p>	1,6-10

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB2004/003235

**Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.b of the first sheet)**

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, the international search was carried out on the basis of:
  - a. type of material
    - ☒ a sequence listing
    - ☐ table(s) related to the sequence listing
  - b. format of material
    - ☒ in written format
    - ☒ in computer readable form
  - c. time of filing/furnishing
    - ☐ contained in the international application as filed
    - ☐ filed together with the international application in computer readable form
    - ☒ furnished subsequently to this Authority for the purpose of search
2. ☐ In addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
3. Additional comments:

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB2004/003235

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0212239	A	14-02-2002	FR 2812878 A1	15-02-2002
			FR 2816619 A1	17-05-2002
			AU 8226701 A	18-02-2002
			BG 107460 A	30-09-2003
			BR 0113046 A	01-07-2003
			CA 2412368 A1	14-02-2002
			CN 1446218 T	01-10-2003
			CZ 20030354 A3	14-05-2003
			EP 1309594 A1	14-05-2003
			WO 0212239 A1	14-02-2002
			HU 0301514 A2	29-09-2003
			JP 2004505975 T	26-02-2004
			NO 20030596 A	01-04-2003
			SK 1582003 A3	05-08-2003
			US 2003203893 A1	30-10-2003
			ZA 200300479 A	05-02-2004
WO 9524379	A	14-09-1995	AT 184271 T	15-09-1999
			AT 210651 T	15-12-2001
			AT 231494 T	15-02-2003
			AU 693167 B2	25-06-1998
			AU 1856595 A	25-09-1995
			CA 2184747 A1	14-09-1995
			CA 2350941 A1	14-09-1995
			CA 2352592 A1	14-09-1995
			CN 1143358 A ,B	19-02-1997
			DE 69512036 D1	14-10-1999
			DE 69512036 T2	30-12-1999
			DE 69524641 D1	24-01-2002
			DE 69524641 T2	14-08-2002
			DE 69529482 D1	27-02-2003
			DE 69529482 T2	12-06-2003
			DK 749415 T3	20-03-2000
			DK 879820 T3	02-04-2002
			EP 0749415 A1	27-12-1996
			EP 0879820 A1	25-11-1998
			EP 0897915 A1	24-02-1999
			ES 2135707 T3	01-11-1999
			ES 2169472 T3	01-07-2002
			WO 9524379 A1	14-09-1995
			GR 3031886 T3	29-02-2000
			JP 9510704 T	28-10-1997
			PT 879820 T	28-06-2002
			US 6015827 A	18-01-2000
			US 6316455 B1	13-11-2001
			US 5756510 A	26-05-1998